123 related articles for article (PubMed ID: 38298111)
1. rWTC-MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells.
Wang H; Medina R; Ye J; Zhang Y; Chakraborty S; Valenzuela A; Uher O; Hadrava Vanova K; Sun M; Sang X; Park DM; Zenka J; Gilbert MR; Pacak K; Zhuang Z
Adv Sci (Weinh); 2024 Apr; 11(14):e2308280. PubMed ID: 38298111
[TBL] [Abstract][Full Text] [Related]
2. rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses.
Ye J; Wang H; Medina R; Chakraborty S; Sun M; Valenzuela A; Sang X; Zhang Y; Uher O; Zenka J; Pacak K; Zhuang Z
J Exp Clin Cancer Res; 2023 Jul; 42(1):163. PubMed ID: 37434263
[TBL] [Abstract][Full Text] [Related]
3. Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma.
Lookian PP; Zhao D; Medina R; Wang H; Zenka J; Gilbert MR; Pacak K; Zhuang Z
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810617
[TBL] [Abstract][Full Text] [Related]
4. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
[TBL] [Abstract][Full Text] [Related]
5. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8
Chaib M; Sipe LM; Yarbro JR; Bohm MS; Counts BR; Tanveer U; Pingili AK; Daria D; Marion TN; Carson JA; Thomas PG; Makowski L
Cancer Lett; 2022 Apr; 531():98-108. PubMed ID: 35074498
[TBL] [Abstract][Full Text] [Related]
6. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
[TBL] [Abstract][Full Text] [Related]
7. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
8. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
Simonds EF; Lu ED; Badillo O; Karimi S; Liu EV; Tamaki W; Rancan C; Downey KM; Stultz J; Sinha M; McHenry LK; Nasholm NM; Chuntova P; Sundström A; Genoud V; Shahani SA; Wang LD; Brown CE; Walker PR; Swartling FJ; Fong L; Okada H; Weiss WA; Hellström M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083417
[TBL] [Abstract][Full Text] [Related]
9. Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA).
Medina R; Wang H; Caisová V; Cui J; Indig IH; Uher O; Ye J; Nwankwo A; Sanchez V; Wu T; Nduom E; Heiss J; Gilbert MR; Terabe M; Ho W; Zenka J; Pacak K; Zhuang Z
Adv Ther (Weinh); 2020 Sep; 3(9):. PubMed ID: 33709018
[TBL] [Abstract][Full Text] [Related]
10. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
[TBL] [Abstract][Full Text] [Related]
11. Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations.
Uher O; Caisova V; Padoukova L; Kvardova K; Masakova K; Lencova R; Frejlachova A; Skalickova M; Venhauerova A; Chlastakova A; Hansen P; Chmelar J; Kopecky J; Zhuang Z; Pacak K; Zenka J
Cancer Immunol Immunother; 2021 Nov; 70(11):3303-3312. PubMed ID: 33855601
[TBL] [Abstract][Full Text] [Related]
12. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
13. Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas.
Choi SH; Stuckey DW; Pignatta S; Reinshagen C; Khalsa JK; Roozendaal N; Martinez-Quintanilla J; Tamura K; Keles E; Shah K
Clin Cancer Res; 2017 Nov; 23(22):7047-7058. PubMed ID: 28912136
[No Abstract] [Full Text] [Related]
14. Human CD34
van Eck van der Sluijs J; van Ens D; Brummelman J; Heister D; Sareen A; Truijen L; van Ingen Schenau DS; Heemskerk MHM; Griffioen M; Kester MGD; Schaap NPM; Jansen JH; van der Waart AB; Dolstra H; Hobo W
Cell Mol Life Sci; 2023 Sep; 80(10):298. PubMed ID: 37728691
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
16. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
[TBL] [Abstract][Full Text] [Related]
17. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
18. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
[TBL] [Abstract][Full Text] [Related]
19. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
20. Human dendritic cell subsets in the glioblastoma-associated microenvironment.
Hu X; Jiang C; Gao Y; Xue X
J Neuroimmunol; 2023 Oct; 383():578147. PubMed ID: 37643497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
